These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 4803217)

  • 1. The cure and concomitant immunization of mice bearing Ehrlich ascites tumors by treatment with an antibody--alkylating agent complex.
    Flechner I
    Eur J Cancer (1965); 1973 Oct; 9(10):741-5. PubMed ID: 4803217
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo suppression of Ehrlich ascites carcinoma by human antibody-dependent splenocytes.
    Dobaczewska H
    Neoplasma; 1984; 31(2):165-8. PubMed ID: 6717686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine 3',5'-monophosphate phosphodiesterase activity in experimental animal tumours which are either sensitive or resistant to bifunctional alkylating agents.
    Tisdale MJ; Phillips BJ
    Biochem Pharmacol; 1975 Jan; 24(2):205-10. PubMed ID: 163093
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibodies as carriers of anticancer agents.
    Rubens RD
    Lancet; 1974 Mar; 1(7856):498-9. PubMed ID: 4131895
    [No Abstract]   [Full Text] [Related]  

  • 5. [Differenciation of reaction mechanisms of alkylating cytostatics on Ehrlich ascites-carcinoma- and lymphatic leucemic cells].
    Kummer D; Ochs HD
    Z Krebsforsch; 1970 Mar; 73(4):315-28. PubMed ID: 4245611
    [No Abstract]   [Full Text] [Related]  

  • 6. In vivo suppression of Ehrlich ascites carcinoma by human antibody-dependent leukocytes.
    Dobaczewska H
    Neoplasma; 1982; 29(3):323-5. PubMed ID: 7133227
    [No Abstract]   [Full Text] [Related]  

  • 7. Augmentation of in vivo antitumour activity of xenogeneic antiserum by autotransplanted normal spleen cells in mice.
    Jakóbisiak M; Kańtoch M; Lasek W; Rozmysłowicz T; Obłakowski P; Dobaczewska H
    Eur J Cancer (1965); 1981 Jan; 17(1):77-80. PubMed ID: 7262149
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of specific antibodies and immunocompetent cells on tumor growth in passive transfer experiment.
    Zhigunova AV; Kravtsov EG; Yashina NV; Dalin MV; Karpenko LP
    Bull Exp Biol Med; 2013 Apr; 154(6):762-4. PubMed ID: 23658918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [THE EFFECT OF ALKYLATING CYTOSTATICS ON THE NUCLEIC ACID METABOLISM OF EHRLICH ASCITES TUMOR CELLS].
    LISS E; PALME G
    Z Krebsforsch; 1964 Jul; 66():196-206. PubMed ID: 14256642
    [No Abstract]   [Full Text] [Related]  

  • 10. Suppression of an AKR lymphoma by antibody and chlorambucil.
    Ghose T; Guclu A; Tai J
    J Natl Cancer Inst; 1975 Dec; 55(6):1353-7. PubMed ID: 1107575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ascitic versus solid growth of Ehrlich ascites tumor influenced by immunological factors.
    Culo F; Allegretti N; Marusić M
    Oncology; 1978; 35(1):15-21. PubMed ID: 625393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapeutic effects of compound 593A (NSC-135758) on mouse leukemias and some transplanted animal tumors.
    Tarnowski GS; Schmid FA; Hutchison DJ; Stock CC
    Cancer Chemother Rep; 1973 Feb; 57(1):21-7. PubMed ID: 4704098
    [No Abstract]   [Full Text] [Related]  

  • 13. [Homologous anti-tissue antibodies as a factor supressing the development of malignant tumors].
    Saraeva ZM; Tereshchenko IP; Klemparskaia NN; Shal'nova GA
    Biull Eksp Biol Med; 1977 Oct; 84(10):468-71. PubMed ID: 912060
    [No Abstract]   [Full Text] [Related]  

  • 14. Protection of mice from malignant tumor implants by enucleated tumor cells.
    Sethi KK; Brandis H
    J Natl Cancer Inst; 1974 Oct; 53(4):1175-6. PubMed ID: 4372368
    [No Abstract]   [Full Text] [Related]  

  • 15. [Experimental study on thermodifferential chemotherapy of carcinoma (author's transl)].
    Kamura T; Kidera Y; Aoki K; Nishikawa K; Baba T
    Fukuoka Igaku Zasshi; 1977 Oct; 68(10):492-7. PubMed ID: 590913
    [No Abstract]   [Full Text] [Related]  

  • 16. [Different immunological factors in the therapy of an experimental tumor].
    Nicolin A; Frontini E; Olivani P
    Boll Ist Sieroter Milan; 1971; 50(4):295-8. PubMed ID: 5163498
    [No Abstract]   [Full Text] [Related]  

  • 17. Different behaviour of thymus in hosts bearing skin homografts or ehrlich ascites carcinoma.
    Simu G; Kiricuţă I; Crivii MS; Nestor D
    Arch Geschwulstforsch; 1976; 46(3):183-6. PubMed ID: 9920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibition of the growth of Ehrlich transplantable carcinoma in mice by antichorionic immune serum].
    Dil'man VM; Tsyrlina EV; Bulovskaia LN; Bobrov IuF
    Vopr Onkol; 1983; 29(2):62-4. PubMed ID: 6836972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Migration capacity of tumor cells treated with immune sera].
    Lebedev KA; Kaulen DR; Khorobrykh VV; D'iakov GN; Simonova AV
    Biull Eksp Biol Med; 1977 Dec; 84(12):712-4. PubMed ID: 597608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AUTORADIOGRAPHIC STUDIES OF MOUSE ASCITES TUMORS, C-1498 AND E.L.4, IN SUSCEPTIBLE (C57BL) A RESISTANT (B10.D2) MICE.
    TANAKA KK; ROBERTS E
    Cancer Res; 1964 Nov; 24():1798-809. PubMed ID: 14231924
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.